ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP)
dc.contributor.author | Briassoulis, E. Ch | en |
dc.contributor.author | Ch, F. Tolis | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Briassoulis, E. Ch | en |
dc.creator | Ch, F. Tolis | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:52:45Z | |
dc.date.available | 2018-06-22T09:52:45Z | |
dc.date.issued | 2001 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41485 | |
dc.language.iso | eng | en |
dc.source | Annals of Oncology | en |
dc.subject | Europe | en |
dc.subject | Article | en |
dc.subject | European union | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Cancer | en |
dc.subject | Human | en |
dc.subject | Neoplasms | en |
dc.subject | Patient care | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Cancer patient | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Follow up | en |
dc.subject | Neoplasm staging | en |
dc.subject | Platinum derivative | en |
dc.subject | Priority journal | en |
dc.subject | Human tissue | en |
dc.subject | Treatment planning | en |
dc.subject | Cancer diagnosis | en |
dc.subject | Cancer radiotherapy | en |
dc.subject | Idiopathic disease | en |
dc.subject | Male | en |
dc.subject | Risk assessment | en |
dc.subject | Immunohistochemistry | en |
dc.subject | Cancer risk | en |
dc.subject | Tumor differentiation | en |
dc.subject | Lymph node metastasis | en |
dc.subject | Cancer incidence | en |
dc.subject | Biological | en |
dc.subject | Tumor markers | en |
dc.subject | Unknown primary | en |
dc.subject | Alpha fetoprotein | en |
dc.subject | Cancer palliative therapy | en |
dc.subject | Chorionic gonadotropin beta subunit | en |
dc.subject | Prostate specific antigen | en |
dc.subject | Cancer classification | en |
dc.subject | Clinical protocol | en |
dc.subject | Health care organization | en |
dc.subject | Hormonal therapy | en |
dc.subject | Hormone derivative | en |
dc.subject | Medical assessment | en |
dc.subject | Sex factors | en |
dc.title | ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP) | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1023/A:1017409423484 | |
dc.description.volume | 12 | |
dc.description.issue | 8 | |
dc.description.startingpage | 1057 | |
dc.description.endingpage | 1058 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |